Prof. Dr. Dr. Gerd Geisslinger
Prof. Dr. Dr. Gerd Geisslinger
Professor für Klinische Pharmakologie - Goethe-Universität
Verified email at
Cited by
Cited by
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
I Tegeder, J Pfeilschifter, G Geisslinger
The FASEB Journal 15 (12), 2057-2072, 2001
COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib
S Grösch, I Tegeder, E Niederberger, L Bräutigam, G Geisslinger
The FASEB journal 15 (14), 1-22, 2001
GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence
I Tegeder, M Costigan, RS Griffin, A Abele, I Belfer, H Schmidt, C Ehnert, ...
Nature medicine 12 (11), 1269-1277, 2006
Cyclooxygenase-2 (COX-2)–independent anticarcinogenic effects of selective COX-2 inhibitors
S Grösch, TJ Maier, S Schiffmann, G Geisslinger
Journal of the National Cancer Institute 98 (11), 736-747, 2006
Mutschler Arzneimittelwirkungen
E Mutschler, G Geisslinger, HK Kroemer, M Schäfer-Korting
Lehrbuch der Pharmakologie und Toxikologie 9, 2001
Chain length-specific properties of ceramides
S Grösch, S Schiffmann, G Geisslinger
Progress in lipid research 51 (1), 50-62, 2012
Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
F Beiche, S Scheuerer, K Brune, G Geisslinger, M Goppelt-Struebe
FEBS letters 390 (2), 165-169, 1996
COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites
M Burian, G Geisslinger
Pharmacology & therapeutics 107 (2), 139-154, 2005
Ziconotide for treatment of severe chronic pain
A Schmidtko, J Lötsch, R Freynhagen, G Geisslinger
The Lancet 375 (9725), 1569-1577, 2010
Pharmacokinetics of opioids in liver disease
I Tegeder, J Lötsch, G Geisslinger
Clinical pharmacokinetics 37, 17-40, 1999
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer
E Ruckhäberle, A Rody, K Engels, R Gaetje, G Von Minckwitz, ...
Breast cancer research and treatment 112, 41-52, 2008
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain
M Sisignano, R Baron, K Scholich, G Geisslinger
Nature Reviews Neurology 10 (12), 694-707, 2014
Capturing adenylyl cyclases as potential drug targets
S Pierre, T Eschenhagen, G Geisslinger, K Scholich
Nature reviews Drug discovery 8 (4), 321-335, 2009
Opioids as modulators of cell death and survival—unraveling mechanisms and revealing new indications
I Tegeder, G Geisslinger
Pharmacological reviews 56 (3), 351-369, 2004
The IKK‐NF‐κB pathway: a source for novel molecular drug targets in pain therapy?
E Niederberger, G Geisslinger
The FASEB Journal 22 (10), 3432-3442, 2008
Ceramide synthases and ceramide levels are increased in breast cancer tissue
S Schiffmann, J Sandner, K Birod, I Wobst, C Angioni, E Ruckhäberle, ...
Carcinogenesis 30 (5), 745-752, 2009
Analgesic effects of morphine and morphine‐6‐glucuronide in a transcutaneous electrical pain model in healthy volunteers
C Skarke, J Darimont, H Schmidt, G Geisslinger, J Lötsch
Clinical Pharmacology & Therapeutics 73 (1), 107-121, 2003
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives
J Lötsch, C Skarke, J Liefhold, G Geisslinger
Clinical pharmacokinetics 43, 983-1013, 2004
Cyclooxygenase-2 (COX-2)-dependent and-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells
TJ Maier, K Schilling, R Schmidt, G Geisslinger, S Grösch
Biochemical pharmacology 67 (8), 1469-1478, 2004
Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting
H Dormann, U Muth-Selbach, S Krebs, M Criegee-Rieck, I Tegeder, ...
Drug safety 22, 161-168, 2000
The system can't perform the operation now. Try again later.
Articles 1–20